Wells Fargo analyst Mohit Bansal maintained the stock with an Overweight rating and lowered the price target from $170 to $150. Considering buying BNTX stock? Here’s what analysts think: ...

BioNTech (BNTX) recently experienced a 10% price increase in the last quarter, coinciding with the Health Canada's authorization of its variant-adapted COMIRNATY COVID-19 vaccine, a potential positive ...

The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. BioNTech SE Sponsored ADR (BNTX) is a stock that can certainly grab the ...

Robeco Institutional Asset Management B.V. cut its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 23.5% in the first quarter, according to the company in its most ...

BioNTech SE (NASDAQ:BNTX), a German biotechnology company, specializes in mRNA-based immunotherapies for cancer and infectious diseases and stands eleventh on our list among the best cancer stocks.

This study could significantly impact BioNTech’s stock performance and investor sentiment, as successful results may enhance the company’s position in the oncology market.